Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Business Exposures
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
99 100 Next >
Volvo Recalls 72K New Electric Luxury SUV EX30 Over Software Glitch
Via Benzinga
Topics Product Recall
Exposures Legal Product Safety
Psychedelics Stocks Are Falling After a Shocking Vote at the FDA. Here's What You Need to Know.
Via The Motley Fool
Exposures Product Safety
Tickers CMPS
Abbott Snags U.S. Clearance To Enter The Obesity Arena, Rivaling Dexcom
Via Investor's Business Daily
Exposures Product Safety
Tickers ABT DXCM LLY NVO
Geron Corporation: FDA Approval Fuels Stock Price Surge
Via MarketBeat
Exposures Product Safety
Tickers GERN
Moderna Seeks FDA Approval For Updated COVID-19 Shot For Upcoming Season
Via Benzinga
Exposures COVID-19 Product Safety
Tickers BNTX MRNA NVAX PFE
Kia Recalls Over 460K Telluride SUVs In US Due To Fire Risk From Overheating Seat Motors
Via Benzinga
Topics Product Recall
Exposures Legal Product Safety
VSA Celebrates 20-Year Partnership with Software Provider Tayrex
Via PRLog
Topics Product Recall
Exposures COVID-19 Legal Product Safety
Why Biomea Fusion (BMEA) Stock Is Down 60%
Via Benzinga
Exposures Product Safety
Tickers BMEA
FDA Reverses Juul Ban. What Comes Next?
Via InvestorPlace
Exposures Product Safety
Tickers GERN GME
Why Is Geron (GERN) Stock Up 18% Today?
Via InvestorPlace
Exposures Product Safety
Tickers AAPL GERN NVDA
FDA Approves Geron's First Commercial Drug, Competes With Bristol Myers Squibb's Blood Cancer Drug
Via Benzinga
Exposures Product Safety
Tickers BMY GERN
Biomea Fusion Crashes 65% After FDA Puts Diabetes Treatment Studies On Hold
Via Investor's Business Daily
Exposures Product Safety
Tickers BMEA
Theriva Biologics Receives Fast Track Designation From FDA For VCN-01 For Treating Metastatic Pancreatic Cancer
Via News Direct
Exposures Product Safety
Tickers TOVX
Why Is Biomea Fusion (BMEA) Stock Down 63% Today?
Via InvestorPlace
Exposures Product Safety
Tickers BMEA
This Pharma Stock Dropped 60% Premarket As FDA Halted Diabetes Drug Trials
Via Benzinga
Exposures Product Safety
Tickers BMEA
Telegram's Pavel Durov Recalls 'Funny' 2009 Meeting With Mark Zuckerberg: 'They Ended Up Trying To Copy Not What We Did, But What I Told Them We Did'
Via Benzinga
Topics Product Recall
Exposures Legal Product Safety
Some Breather For E-Cigarette Maker Juul As FDA Reconsiders Marketing Denials Issued Two Years Ago
Via Benzinga
Exposures Product Safety
Tickers MO
Novavax Stock’s Recent Surge and Future Potential
Via MarketBeat
Topics Economy
Exposures COVID-19 Product Safety Supply Chain
Tickers MRNA NVAX PFE
Eli Lilly's Alzheimer's Drug, Donanemab Faces FDA's Adcomm Vote Next Week On Data, Risk Profile
Via Benzinga
Exposures Product Safety
Tickers LLY
Novavax Stock Soars On FDA COVID-19 Update: Fundamental Rally Or Potential Short Squeeze?
Via Benzinga
Exposures COVID-19 Product Safety
Tickers NVAX
FDA Committee 'Completely Lost Sight Of The Big Picture' Says Retired Lieutenant General Urging Approval On MDMA For PTSD
Via Benzinga
Exposures Product Safety
FDA Selects Moderna's Rare Disease Candidate For Accelerated Development Program
Via Benzinga
Exposures Product Safety
Tickers MRNA
What's Going On With Novavax Stock Thursday?
Via Benzinga
Exposures COVID-19 Product Safety
Tickers NVAX
Novavax, With A 369% Gain, Tears Ahead Again On Key FDA Move
Via Investor's Business Daily
Exposures COVID-19 Product Safety
Tickers MRNA NVAX PFE
Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment
Via Benzinga
Exposures Product Safety
Tickers ATAI CYBN MNMD PSIL
Medtronic Recalls Some Versions Of Software Used For Cranial Surgery
Via Benzinga
Topics Product Recall
Exposures Legal Product Safety
Tickers MDT
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Completion of Dosing in Second Arm of Third GLP-1 Human Pilot Study
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Tickers LEXX
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Reports Completion of Dosing in Second Arm of Third GLP-1 Human Pilot Study
Via CannabisNewsWire
Topics Intellectual Property
Exposures Intellectual Property Product Safety
Tickers LEXX
FDA Panel Rejects MDMA Therapy For PTSD, Citing Concerns Over Research Data In Setback For Advocates
Via Benzinga
Exposures Product Safety
Nihar Gala Unveils Innovative Solution for Fitness Goals: Compounded Semaglutide Now Available at Alpha Care Medical
Via Get News
Exposures Product Safety
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.